Compare IVR & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVR | DNA |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 595.9M | 562.3M |
| IPO Year | 2009 | N/A |
| Metric | IVR | DNA |
|---|---|---|
| Price | $8.12 | $9.39 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $7.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.3M | 979.7K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 16.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | $72,304,000.00 | ★ $180,606,000.00 |
| Revenue This Year | $271.79 | N/A |
| Revenue Next Year | N/A | $7.28 |
| P/E Ratio | $15.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.86 | $5.00 |
| 52 Week High | $9.06 | $17.58 |
| Indicator | IVR | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 58.30 | 47.51 |
| Support Level | $8.05 | $8.56 |
| Resistance Level | $8.40 | $10.05 |
| Average True Range (ATR) | 0.14 | 0.55 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 58.21 | 65.25 |
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.